Per Malmström
11 – 20 of 159
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2020
-
Mark
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer : Results from the phase 3 PANTHER trial
- Contribution to journal › Article
-
Mark
Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast-conserving surgery : a long-term follow-up of the SweBCG91-RT randomised trial
- Contribution to journal › Article
-
Mark
No Increased Cardiac Mortality or Morbidity of Radiation Therapy in Breast Cancer Patients After Breast-Conserving Surgery : 20-Year Follow-up of the Randomized SweBCGRT Trial
- Contribution to journal › Article
-
Mark
Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis : a population-based study
- Contribution to journal › Article
-
Mark
Kommentar angående tidigare artikel
- Contribution to specialist publication or newspaper › Specialist publication article
- 2019
-
Mark
Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities : further results from the prospective PANTHER study with focus on obese patients
(2019) In Annals of oncology : official journal of the European Society for Medical Oncology 30(1). p.109-114
- Contribution to journal › Article
-
Mark
Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes : A Long-Term Follow-Up of the SweBCG91RT Randomized Trial
- Contribution to journal › Article
-
Mark
Clinicogenomic radiotherapy classifier predicting the need for intensified locoregional treatment after breast-conserving surgery for early-stage breast cancer
- Contribution to journal › Article
- 2018
-
Mark
Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment
- Contribution to journal › Article
-
Mark
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
- Contribution to journal › Article
